Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Collagenase injection Clear all
Completed Phase 2 Interventional Results available

AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder

NCT01483963
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder
Interventions
AA4500 0.29 mg/1 mL, AA4500 0.58 mg/2 mL, AA4500 0.58 mg/1 mL, AA4500 0.58 mg/0.5 mL, Shoulder exercises
Biological · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 25, 2026, 10:55 PM EDT
Not listed Phase 4 Interventional

Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

NCT03767452
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Xiaflex® 0.58 mg
Drug
Lead sponsor
Manhattan Medical Research Practice, PLLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

NCT00528840
View directory record Official record
Conditions
Advanced Dupuytren's Disease
Interventions
collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Burbank, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

NCT02889848
View directory record Official record
Conditions
Fibroids, Uterine, Leiomyoma
Interventions
Saline, EN3835
Other · Drug
Lead sponsor
Advance Biofactures Corporation
Industry
Eligibility
35 Years to 50 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Histopathology Following CCH Injection

NCT04236635
View directory record Official record
Conditions
Characteristics of Subcutaneous Tissue
Interventions
Collagenase Clostridium Histolyticum Single Injection Technique, Collagenase Clostridium Histolyticum Multiple Injection Technique
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Montclair, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 4 Interventional

Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

NCT05108558
View directory record Official record
Conditions
Peyronie's Disease
Interventions
CCH administration, Control - Crossover to CCH, RestoreX
Drug · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 3 Interventional Results available

Administration of Two Injections for Multiple Dupuytren's Contractures

NCT01407068
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
AA4500 collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • Indianapolis, Indiana • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 4 Interventional

Xiaflex® Plus Testosterone Treatment Pilot Study Protocol

NCT03815331
View directory record Official record
Conditions
Peyronie's Disease (PD)
Interventions
Xiaflex®, Aveed
Drug
Lead sponsor
Men's Health Boston
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 2 Interventional

A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)

NCT06169319
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Collagenase Clostridium Histolyticum (CCH), Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
39
States / cities
Tucson, Arizona • Castro Valley, California • Corona, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 25, 2026, 10:55 PM EDT
Completed No phase listed Observational

Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity

NCT05249257
View directory record Official record
Conditions
Cellulite, Laxity; Skin, Edematous Fibrosclerotic Panniculopathy
Interventions
Not listed
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Coral Gables, Florida • Metairie, Louisiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 1Phase 2 Interventional

Collagenase in the Treatment of Zone II Flexor Tendon Adhesions in the Hand

NCT00261209
View directory record Official record
Conditions
Adhesion of Flexor Tendon of Hand
Interventions
Collagenase, Collagenase injection
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Sep 25, 2026, 10:55 PM EDT
Active, not recruiting Phase 4 Interventional

Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease

NCT06649539
View directory record Official record
Conditions
Peyronie Disease
Interventions
Collagenase Clostridium Histolyticum, RestoreX, Sildenafil
Drug · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 25, 2026, 10:55 PM EDT
Not yet recruiting Early Phase 1 Interventional

Collagenase Injection for Spasticity Management

NCT07693569
View directory record Official record
Conditions
Spasticity
Interventions
XIAFLEX Collagenase injection
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effectiveness of Splinting After Collagenase Injection

NCT04874870
View directory record Official record
Conditions
Dupuytren Contracture, Dupuytren's Disease
Interventions
Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex], Xiaflex + Hand-Based Custom Orthosis
Drug · Combination Product
Lead sponsor
Foundation for Orthopaedic Research and Education
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques

NCT04580303
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite, Laxity; Skin
Interventions
collagenase clostridium histolyticum
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Coral Gables, Florida • Metairie, Louisiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 25, 2026, 10:55 PM EDT
Active, not recruiting Phase 4 Interventional

Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease

NCT05777031
View directory record Official record
Conditions
Peyronie Disease, Sexual Dysfunctions, Psychological, Genital Diseases, Male
Interventions
Collagenase Clostridium Histolyticum (CCH)
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 25, 2026, 10:55 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's

NCT04786106
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH), Penile Plication Surgery, Incision and Grafting (I&G) Surgery, RestoreX Penile Traction Device
Drug · Procedure · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of EN3835 in the Treatment of EFP in Women

NCT03329989
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
Collagenase Clostridium Histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Scottsdale, Arizona • Huntington Beach, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT02724644
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, Placebo Comparator
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
16
States / cities
Beverly Hills, California • Murrieta, California • Oceanside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite.

NCT05026216
View directory record Official record
Conditions
Cellulite
Interventions
Qwo
Drug
Lead sponsor
DMR Research, PLLC
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Westport, Connecticut
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease

NCT01430169
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 25, 2026, 10:55 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture

NCT01226121
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
Clostridial collagenase injectable
Biological
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Indianaplis, Indiana • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Oral TXA on Buttock Bruising Post CCH Injections in Adult Females

NCT05309525
View directory record Official record
Conditions
Cellulite
Interventions
Collagenase Clostridium Histolyticum-Aaes, Lysteda 650 MG Oral Tablet
Drug
Lead sponsor
Luxurgery
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 25, 2026, 10:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)

NCT03632993
View directory record Official record
Conditions
Edematous Skin
Interventions
collagenase clostridium histolyticum (CCH)
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Coral Gables, Florida • Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 25, 2026, 10:55 PM EDT